Dabague J, Reyes PA Takayasu arteritis in Mexico: a 38-year clinical perspective through literature review. Int J Cardiol. 1996 Aug;54 Suppl:S103-9. Review.
Hoffman GS Takayasu arteritis: lessons from the American National Institutes of Health experience. Int J Cardiol. 1996 Aug;54 Suppl:S99-102.
Ishikawa K Natural history and classification of occlusive thromboaortopathy (Takayasu's disease). Circulation. 1978 Jan;57(1):27-35.
Kaku Y, Aomi S, Tomioka H, Yamazaki K Surgery for aortic regurgitation and aortic root dilatation in Takayasu arteritis. Asian Cardiovasc Thorac Ann. 2015 Oct;23(8):901-6. doi: 10.1177/0218492315591291. Epub 2015 Jun 18.
Lazzarin P, Pasero G, Marson P, Cecchetto A, Zanchin G [Takayasu's arteritis. A concise review and some observations on a putative case reported by Giovanni Battista Morgagni (1761)]. Reumatismo. 2005 Dec;57(4):305-13. Italian.
Park SJ, Kim HJ, Park H, Hann HJ, Kim KH, Han S, Kim Y, Ahn HS Corrigendum to "Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea - A nationwide, population-based study" [Int. J. Cardiol., 235(2017), 100-104]. Int J Cardiol. 2017 Jul 1;238:182. doi: 10.1016/j.ijcard.2017.04.013. Epub 2017 Apr 24.
Rosa Neto NS, Shinjo SK, Levy-Neto M, Pereira RMR Vascular surgery: the main risk factor for mortality in 146 Takayasu arteritis patients. Rheumatol Int. 2017 Jul;37(7):1065-1073. doi: 10.1007/s00296-017-3656-y. Epub 2017 Feb 21.
Soto ME, Espinola N, Flores-Suarez LF, Reyes PA Takayasu arteritis: clinical features in 110 Mexican Mestizo patients and cardiovascular impact on survival and prognosis. Clin Exp Rheumatol. 2008 May-Jun;26(3 Suppl 49):S9-15.
The Long-term Success of Cardiovascular Surgery in Takayasu Arteritis. 30 Years of Experience in Mexico, Beyond Forefront Techniques
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
